Graduate Institute of Biomedical Sciences and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Division of Nephrology and Kidney Institute, China Medical University Hospital, Taichung, Taiwan.
Int J Clin Pract. 2021 Sep;75(9):e14416. doi: 10.1111/ijcp.14416. Epub 2021 Jun 12.
We aimed to investigate whether the risk of diabetes mellitus (DM) is heightened in patients with prostate cancer receiving injection therapy.
Men diagnosed with prostate cancer between 2000 and 2012 were included in the case cohort, and men without prostate cancer were included as controls. Each patient with prostate cancer was matched with a control patient with the same index year, demographic variables and comorbidities, and comparisons were made using propensity score matching. The hazard ratio of DM was estimated using the Cox proportional hazards model.
This cohort study consisted of 1213 patients with prostate cancer and 1213 control patients. The risk of DM in patients with prostate cancer was 1.60 times (95% CI = 1.12, 2.27) that of patients without prostate cancer. Compared with the controls, the hazard ratios of DM for patients with prostate cancer not receiving oral hormone therapy, patients with prostate cancer receiving oral hormone therapy, and patients with prostate cancer not receiving injection hormone therapy were 1.65 (95% CI = 1.01, 2.70), 1.57 (95% CI = 1.07, 2.70), and 1.94 (95% CI = 1.34, 2.81), respectively. The risk of DM in patients who received injection hormone therapy was 0.45 times (95% CI = 0.25, 0.82) that of patients who did not receive injection hormone therapy.
Patients with prostate cancer had an increased risk of DM compared with patients without prostate cancer. Patients with prostate cancer who received injection therapy had a lower risk of DM compared with those who did not.
我们旨在研究接受注射治疗的前列腺癌患者发生糖尿病（DM）的风险是否升高。
本病例队列纳入了 2000 年至 2012 年间诊断为前列腺癌的男性患者，将无前列腺癌的男性纳入对照组。每例前列腺癌患者均与同一年索引、人口统计学变量和合并症相匹配的对照患者进行匹配，并使用倾向评分匹配进行比较。使用 Cox 比例风险模型估计 DM 的风险比。
这项队列研究共纳入了 1213 例前列腺癌患者和 1213 例对照患者。患有前列腺癌的患者发生 DM 的风险是未患有前列腺癌的患者的 1.60 倍（95%CI=1.12，2.27）。与对照组相比，未接受口服激素治疗的前列腺癌患者、接受口服激素治疗的前列腺癌患者和未接受注射激素治疗的前列腺癌患者的 DM 风险比分别为 1.65（95%CI=1.01，2.70）、1.57（95%CI=1.07，2.70）和 1.94（95%CI=1.34，2.81）。接受注射激素治疗的患者发生 DM 的风险是未接受注射激素治疗的患者的 0.45 倍（95%CI=0.25，0.82）。
与无前列腺癌的患者相比，患有前列腺癌的患者发生 DM 的风险增加。与未接受注射治疗的患者相比，接受注射治疗的前列腺癌患者发生 DM 的风险较低。
